HOME >> MEDICINE >> NEWS
ZYVOX(R) demonstrates high success rate for patients who develop MRSA surgical site infections

New York, Dec. 15, 2004 Surgical patients treated with Pfizer's novel antibiotic ZYVOX (linezolid; injection, tablets, and for oral suspension) had a significantly higher rate of microbiologic success (documented or presumed eradication) than those treated with intravenous (IV) vancomycin for surgical site infections (SSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA), according to data published in the December issue of the American Journal of Surgery. In addition, the mean duration of IV treatment was significantly shorter (6 days) for patients who received ZYVOX than for those treated with vancomycin. Post-operative surgical site infections remain a major source of illness and number approximately 500,000 per year.

In the post-hoc analysis, patients in the MRSA subgroup treated with ZYVOX had microbiologic success rates of 87 percent compared to 48 percent for patients on vancomycin. Clinical cure rates for ZYVOX-treated patients were comparable to those treated with vancomycin for all SSIs, including those caused by MRSA. ZYVOX, available in interchangeable IV and oral formulations, is the only oral therapy approved by the U.S. Food and Drug Administration for MRSA infections.

Patients who develop SSIs are 60 percent more likely to spend time in an intensive care unit, five times more likely to be readmitted to the hospital and twice as likely to die. Hard-to-treat resistant bacteria such as MRSA are further complicating these infections. MRSA is extremely serious and can lead to prolonged hospitalization, increased morbidity, increased risk of mortality, and increased costs (driven by length of hospital stay). Data show that MRSA caused 30 percent of SSIs in 2000 compared to 24 percent in 1997.

"As the prevalence of surgical site infections caused by MRSA increases, identifying MRSA early and having alternatives to vancomycin becomes extremely important since any patient undergoing surgery is at risk," said
'"/>

Contact: Jeanne Traflet
Jeanne.Traflet@Pfizer.com
212-733-0127
Edelman Public Relations
15-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. New study in Nature demonstrates protection against cell death during heart attack
2. New study demonstrates co-administration
3. New data demonstrates that Benicar(R) and Benicar HCT (TM) achieve JNC 7 blood pressure goals
4. New study demonstrates significant and sustained improvements in BPH symptoms with AVODART ™
5. New Canadian study demonstrates clear survival benefit of treatment in trials and at large centres
6. New study demonstrates key benefits of RISPERDAL(R) CONSTA(R) in young adults with schizophrenia
7. UF smart home demonstrates concept of automated elderly help and care
8. Study demonstrates improved survival in women with metastatic breast cancer
9. CHARM* Programme demonstrates clear benefits of Atacand in the treatment of heart failure
10. Residential addiction treatment demonstrates economic benefits
11. New P.E. study demonstrates vigorous exercise can lower adolescents body fat, blood pressure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/8/2019)... ... ... Over the past three decades, Buffalo Wings & Rings has elevated the chicken ... a higher-quality product and experience than the competition. Now, the club-level sports restaurant brand ... FOR THE CAUSE" campaign in support of Breast Cancer Awareness Month. , “We ...
(Date:10/8/2019)... ANNAPOLIS, Md. (PRWEB) , ... October 08, 2019 , ... ... IV, metastatic breast cancer, announced the launch of its Stage IV Stampede campaign. The ... 11, 2019 in Washington, DC that will include an advocacy boot camp, a march, ...
(Date:10/8/2019)... FAYETTEVILLE, Ark. (PRWEB) , ... October 08, 2019 ... ... Hub has selected CardioWise, Inc. a Digital Health Awards 1st Round ... of UCSF Digital Health Awards was to select companies that promote faster, better, ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Marc Lazare, a ... an advanced Level III training in Cagliari, Italy, this past September to further ... September 16-19, 2019 at the Sardinia Dental Teaching Center and covered several advanced ...
(Date:10/8/2019)... ... , ... Fewer than 50 percent of preclinical research studies, ... bioanalytical method validation is emerging in the form of a global standard: preclinical ... and senior scientists add the management of an offshore team to their duties. ...
Breaking Medicine News(10 mins):
(Date:10/11/2019)... ... 2019 , ... The 'W' Initiative, a flagship women empowerment ... Month. The plans are aimed at improving community awareness on health issues that ... health checks and encouraging healthy lifestyle habits. , Slated to run all through ...
(Date:10/11/2019)... ... 2019 , ... MindShare Technology Founder and CEO Greg Povolny will offer his ... Families and Communities National Conference. The conference is at the Westin Indianapolis hotel in ... p.m. , Povolny’s presentation will provide real world examples of how to apply ...
(Date:10/10/2019)... ... October 10, 2019 , ... This World Sight Day, we honor ... ireland® is pleased to announce their recent interview with Brand Manager Lynn Hicks ... help consumers of all abilities identify and choose effective hair care products. , ...
Breaking Medicine Technology:
Cached News: